• SPX
  • $5,712.69
  • -0.28 %
  • -$16.11
  • DJI
  • $41,866.81
  • 0.17 %
  • $72.20
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,160.03
  • -0.3 %
  • -$24.21
  • IXIC
  • $18,315.38
  • 0.74 %
  • $135.40
Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Price, News & Analysis

Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Price, News & Analysis

Currency in USD Disclaimer

$7.76

-$0.09

(-1.15%)

Day's range
$7.76
Day's range
$7.78
50-day range
$6.85
Day's range
$10.16
  • Country: US
  • ISIN: US0048901096
52 wk range
$3.19
Day's range
$11.9
  • CEO: Dr. Peter Blume-Jensen M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 8.92
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (ACRV)
  • Company Acrivon Therapeutics, Inc. Common Stock
  • Price $7.76
  • Changes Percentage (-1.15%)
  • Change -$0.09
  • Day Low $7.76
  • Day High $7.78
  • Year High $11.90

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/07/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $20.00
  • High Stock Price Target $30.00
  • Low Stock Price Target $17.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.89
  • Trailing P/E Ratio -2.51
  • Forward P/E Ratio -2.51
  • P/E Growth -2.51
  • Net Income $-60,388,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.